95
Participants
Start Date
August 2, 2019
Primary Completion Date
October 4, 2022
Study Completion Date
October 4, 2022
Derazantinib 300 mg once daily monotherapy
Derazantinib was administered orally at a dose of 300 mg once daily
Derazantinib 200 mg once daily + atezolizumab 1200 mg
Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Derazantinib 300 mg once daily+ atezolizumab 1200 mg
Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Derazantinib 200 mg twice daily + atezolizumab 1200 mg
Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
Derazantinib 300 mg once daily monotherapy (QD)
Derazantinib was administered orally at a dose of 300 mg once daily
Derazantinib 300 mg once daily + atezolizumab 1200 mg
Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Derazantinib 200 mg twice daily monotherapy
Derazantinib was administered orally at a dose of 200 mg twice daily
Lausanne University Hospital, Lausanne
Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) - Universitaetsklinik fuer Urologie, Vienna
National Institute of Oncology, Budapest
Canberra Hospital and Health Services, Canberra
Westmead Hospital, Westmead
Ballarat Oncology & Haematology Services, Wendouree
Yonsei University Health System, Seoul
John Flynn Private Hospital, Tugun
Coastal Cancer Care, Birtinya
Asan Medical Center, Seoul
Bacs- Kiskun Megyei Korhaz, Kecskemét
Seoul St. Marys Hospital Catholic University of Korea, Seoul
Kantonsspital Graubünden, Chur
Hospital del Mar, Barcelona
IOB - Hospital Quiron Salud, Barcelona
UniversitaetsSpital Zuerich, Zurich
ICO Hospitalet, Barcelona
Englander Institute Weill Cornell Medicine, New York
Campus Charite Mitte, Berlin
National Cancer Center, Goyang-si
New York Cancer and Blood Specialists, Port Jefferson Station
CHU Timone / CEPCM, Marseille
Seoul National University Bundang Hospital, Seongnam-si
Centre François Baclesse, Caen
Hospital Universitario Virgen Macarena, Seville
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
IRCCS Ospedale San Raffaele, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
IRCCS - Istituto Europeo di Oncologia IEO, Milan
Gachon University Gil Medical Center, Incheon
ASST Valtellina e Alto Lario - UOC Oncologia Medica Ospedale di Sondrio, Sondrio
Hospital Universitario HM Sanchinarro CIOCC, Madrid
CTCA Clinical Research Inc., Atlanta, Newnan
IUCT-Oncopole de Toulouse, Toulouse
Chungnam National University Hospital, Daejeon
Marques de Valdecilla University Hospital, Santander
Universitaetsklinikum Magdeburg A.oe.R, Magdeburg
Universitaetsklinikum Duesseldorf, Düsseldorf
Hospital Universitario Virgen del Rocio, Seville
Inje University Haeundae Paik Hospital, Busan
Pusan National University Hospital, Busan
Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte, Siena
Fakultni nemocnice u sv. Anny v Brne, Brno
Studienpraxis Urologie, Nürtingen
Medical Oncology - Pitié-Salpêtrière Hopital, Paris
MD Anderson, Houston
Fakultni Nemocnice Olomouc, Olomouc
NEXT Oncology, San Antonio
University Clinic Erlangen, Erlangen
Institut Gustave Roussy, Villejuif
Medical Oncology Associates PS (dba Summit Cancer Centers), Spokane
University of Texas Southwestern Medical Center (UTSWMC), Dallas
Princess Margaret Hospital, Toronto
Juravinski Cancer Center, Hamilton
Institut Bergonie, Bordeaux
Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego, Lublin
Med-Polonia Sp. z o. o., Poznan
Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., 04-073, Warszawa, Poland, Warsaw
Mazowiecki Szpital Onkologiczny, Wieliszew
Korea University Anam Hospital, Seoul
Seoul National University Hospital, Seoul
Vall d Hebron Hospital, Barcelona
Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI), London
The Sarah Cannon Research Institute, London
University College London Hospitals, London
The Royal Marsden NHS Foundation Trust, Sutton
Lead Sponsor
Basilea Pharmaceutica
INDUSTRY